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Abstract
Background: The Centers for Disease Control recommend screening for asymptomatic sexually transmitted infection (STI)
among HIV-infected men when there is self-report of unprotected anal-receptive exposure. The study goals were: (1) to
estimate the validity and usefulness for screening policies of self-reported unprotected anal-receptive exposure as a risk
indicator for asymptomatic anorectal infection with Neisseria gonorrhoeae (GC) and/or Chlamydia trachomatis (CT). (2) to
estimate the number of infections that would be missed if anal diagnostic assays were not performed among patients who
denied unprotected anorectal exposure in the preceding month.
Methods and Findings: Retrospective analysis in HIV primary care and high resolution anoscopy (HRA) clinics. HIV-infected
adult men were screened for self-reported exposure during the previous month at all primary care and HRA appointments.
Four sub-cohorts were defined based on microbiology methodology (GC culture and CT direct fluorescent antibody vs. GC/
CT nucleic acid amplification test) and clinical setting (primary care vs. HRA). Screening question operating characteristics
were estimated using contingency table methods and then pooled across subcohorts. Among 803 patients, the prevalence
of anorectal GC/CT varied from 3.5–20.1% in the 4 sub-cohorts. The sensitivity of the screening question for self-reported
exposure to predict anorectal STI was higher in the primary care than in the HRA clinic, 86–100% vs. 12–35%, respectively.
The negative predictive value of the screening question to predict asymptomatic anorectal STI was $90% in all sub-cohorts.
In sensitivity analyses, the probability of being an unidentified case among those denying exposure increased from 0.4–
8.1% in the primary care setting, and from 0.9–18.8% in the HRA setting as the prevalence varied from 1–20%.
Conclusion: As STI prevalence increases, denial of unprotected anal-receptive exposure leads to an increasingly
unacceptable proportion of unidentified asymptomatic anorectal STI if used as a criterion not to obtain microbiologic
assays.
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Introduction
The Centers for Disease Control (CDC) recommendation for
anorectal screening for asymptomatic sexually transmitted infec-
tion (STI) among HIV-infected men who have sex with men
(MSM) is ‘‘to test for rectal infection with Neisseria gonorrhoeae
(GC) and Chlamydia trachomatis (CT) in men who acknowledge
anal-receptive intercourse during the preceding year’’ [1].
Similarly, the Infectious Diseases Society of America (IDSA)
recommends rectal testing for GC/CT infection ‘‘on the basis of
report of receptive anal intercourse’’ [2]. According to these
recommendations, screening for asymptomatic anorectal STI
depends on the patient’s self-report of unprotected anal-receptive
exposure. In the absence of anorectal symptoms related to an STI,
patients may not perceive themselves to be at risk and may
therefore not request screening. Furthermore, from the medical
provider’s perspective, microbiological ascertainment of asymp-
tomatic anorectal STI is a relatively time consuming procedure in
busy HIV primary care settings [3].
The objectives of this study were to estimate:(1) the prevalence
of asymptomatic anorectal STI in an HIV-infected male
population under care;(2) the sensitivity, specificity, positive and
negative predictive values of self-reported unprotected anorectal
exposure in the preceding month for anorectal infection with GC
and/or CT; and (3) the number of infections that would be missed
if anal diagnostic assays were not performed among patients who
denied unprotected anorectal exposure in the preceding month.
Materials and Methods
The study was a retrospective analysis conducted in a HIV
primary care clinic and its co-located high resolution anoscopy
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All study participants were adult HIV-positive men. This study
was conducted according to the principles expressed in the
Declaration of Helsinki. The study was approved by the
Institutional Review Board of the UCSD Human Research
Protection Program, project# 071931. All patients provided
written informed consent for the collection of samples and
subsequent analysis.
As part of routine care, a brief self-report screening instrument
for unprotected anorectal exposure during the previous month was
implemented at all primary care and HRA clinic visits. The self-
administered assessment of recent sexual risk behaviors is available
at: http://health.ucsd.edu/owenclinic/PatientSurveyForms.html.
The initial evaluation of the screening tool was previously
published [4]. The questions used to screen for unprotected
anorectal exposure were: (a) in the primary care clinic, ‘‘During
the past month, did your partner put his penis in your anus
without using a condom even once?’’ (screening considered
positive for ‘‘yes’’ response) and (b) in the HRA clinic, ‘‘During
the last month, with how many people have you had anal-
receptive sex without using a condom?’’(screening considered
positive for one or more partner) The selection of these items was
based on patient focus group findings and pilot testing for
acceptability and comprehension. The surveys were explained by
the medical assistant at the time vital signs were recorded and then
self- administered on paper by the patient. The completed forms
were given to the clinician and it was the responsibility of the
clinician to obtain microbiologic samples during the primary care
visit or HRA procedure based on agreed upon screening criteria
(see below).
In the primary care clinic, patients were seen at least three times
per year. Selective screening for anal STI was recommended
based on the self-reported numbers of sex partners in the
preceding month (30-day period). In the primary care cohort
between September 2003- June 2008, screening was recommend-
ed if the patient reported at least 1 sex partner during the
preceding month. Beginning July 2008, screening was recom-
mended if the patient reported at least 3 sex partners during the
preceding month. In the HRA clinic, collection of rectal swabs for
STI is a routine part of the procedure for all patients.
Before July 2008, microbiologic investigation for anorectal CT
and GC included direct fluorescent antibody (DFA) assay,
(PathoDx Diagnostic Products Corporation, Los Angeles, Calif.)
and cultures using modified Thayer-Martin media, respectively
[5]. In July 2008, UCSD completed the validation process for the
use of nucleic amplification tests (NAAT) of anorectal samples for
diagnosis of CT and GC infections according to Clinical
Laboratory Improvement Amendments (CLIA) regulations [6].
In both settings, we switched to NAAT assays for diagnosis of
anorectal CT and GC infections. The NAAT used was the Becton
Dickinson ProbeTec ET (Sparks, MD) assay, which has a
sensitivity of 76.5–77.8% and a specificity above 99% for diagnosis
of rectal GC and CT infections among MSM, respectively [7,8].
All patients who tested positive for GC or CT in any microbiology
assay were treated according to the standard of care.
Four sub-cohorts were defined based on a) methods of
microbiologic diagnostic assays: GC culture and CT DFA vs.
GC and CT NAAT; and b) clinical setting: primary care vs. HRA
clinic. Because the four sub-cohorts differed according to inclusion
criterion, clinical setting, screening-question expression, and assay
methodology, we analyzed each separately and then pooled across
subcohorts after examining heterogeneity of effect.
Screening question operating characteristics were estimated as
sensitivity (SE), specificity (SP), positive predictive value (PPV), and
negative predictive value (NPV) for asymptomatic anorectal STI.
The pooled SE and SP of self-reported unprotected anorectal
exposure were estimated using a random-effects model imple-
mented in STATA version 11 (StataCorp, College Station, Texas,
USA).Heterogeneity among sub-cohorts was assessed using the I-
squared statistic [9] and heterogeneity chi-squared test. Finally, to
estimate the probability of unidentified anorectal STI among
patients who denied unprotected exposure in the preceding month
if anal diagnostic assays were not performed (1–NPV), we
conducted sensitivity analyses based on the pooled screening
question SE and SP from our data, varying the prevalence of
asymptomatic anorectal STI from 1–20%. We also modeled,
under varying prevalence, the number of undiagnosed asymp-
tomatic anorectal STI cases in a hypothetical cohort of 1000
patients under the assumption that those not disclosing exposure
would not be screened with a microbiologic assay, while those
acknowledging exposure would all be screened with an assay with
100 percent sensitivity and specificity to detect anorectal
gonorrhea and Chlamydia trachomatis infection. Hypothesis tests
were 2-sided with an alpha error of 0.05.
Results
Between September 2003 and May 2009, 803 male patients
(40.2% of all males under care) were screened: 38.2% were non-
white, 82% reported MSM as their main HIV risk factor, and
median CD4 and log10-transformed HIV viral load were 441
(Interquartile range [IQR]: 298–643) and 1.70 (IQR: 1.68–2.03),
respectively. The study participants were divided into four sub-
cohorts: a) Primary care clinic screened using GC culture and CT
DFA; b) Primary care clinic screened using NAAT; c) HRA clinic
screened using GC culture and CT DFA; and d) HRA clinic
screened using NAAT. Patients enrolled in the four sub-cohorts
completed a total of 1,155 screening visits (Table 1).
In the two primary care sub-cohorts, clinician compliance with
screening recommendations was sub-optimal. In the primary care
sub-cohort using culture and DFA, 271 patients completed the
screening questionnaire but only 58 (21%) underwent microbio-
logic assessment. The 213 (79%) with missing microbiology assays
appeared to be at lower STI risk compared to those with complete
data based on reported prevalence of at least one episode of
unprotected anorectal exposure during the preceding month (39
vs. 71%, p,0.0001, respectively). For the primary care NAAT
sub-cohort, 11 of 45 (24%) lacked microbiologic assay results.
They also appeared to be at lower STI risk than those with
complete data based on self-reported unprotected anorectal
exposure during the preceding month (36 vs.71%, p=0.07,
respectively).
Prevalence of Asymptomatic Anorectal STI
The prevalence of asymptomatic anorectal STI varied accord-
ing to screening eligibility criteria. For the two HRA sub-cohorts
(universal screening) and the primary care sub-cohort requiring at
least one sex partner during the previous month, the prevalence of
positive assays for anorectal GC and/or CT infection varied from
3.4–4.3% and was similar regardless of assay methodology
(Table 2). However, for the primary care sub-cohort enrolled
using selective screening with a requirement of at least 3 sex partners
during the preceding month, the prevalence was 21% (95%
confidence interval[CI]:9–38) using NAAT. Of note, the preva-
lence of asymptomatic anorectal STI varied according to number
of reported partners during the prior month in the HRA NAAT
sub-cohort:3, 8 and 15% for 0, 1 or $2 self reported partners,
respectively [x
2 (2d.f.) 9.298, p =0.010]. We found no association
Rectal STI in HIV-Infected Men
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prevalence in the other three sub-cohorts, conditional upon sub-
cohort eligibility criteria.
Operating Characteristics of the Screening Questions
The SE of the screening question for self-reported unprotected
anorectal exposure to predict anorectal STI was consistently
higher in the primary care setting than in the HRA clinic, 86–
100% vs. 12–35%, respectively (Table 2). In contrast, the SP of the
screening question to predict a STI was lower in the primary care
setting (30–33%) than in the HRA setting (82–86%). The PPV was
unsurprisingly low in all studied sub-cohorts (2.8–25%) given that
the majority of patients reporting unprotected anorectal exposure
do not acquire anorectal STI. However, the NPV of the screening
question to predict an asymptomatic anorectal STI was 90% or
above among all sub-cohorts (Table 2).
Pooling of Screening Question Operating Characteristics
There was substantial heterogeneity of effect among the four
sub-cohorts (; I-squared inconsistency 90.3%, p,0.001). There-
fore, based on examination of operating characteristics of
individual sub-cohorts, we pooled separately the two primary
care and the two HRA sub-cohorts (Figure 1). For the primary
care sub-cohorts, the pooled SE and SP were 90 and 31%,
respectively. For the HRA sub-cohorts, the pooled SE and SP
were 22 and 84%, respectively.
Sensitivity Analysis
These pooled estimates of SE and SP were applied in sensitivity
analyses to estimate the probability of unidentified asymptomatic
anorectal STI among those denying exposure and therefore not
undergoing microbiologic screening. This probability can be
interpreted as one minus the negative predictive value of the
screening question. We observed that as the prevalence of
anorectal STI varies from 1–20% in settings similar to the
primary care sub-cohorts in this study (pooled SE 90%, SP 31%),
the probability of being an unidentified case among those denying
exposure increases from 0.4–8.1%. In contrast, in settings similar
to the HRA sub-cohorts (SE 22%, SP 84%), as the prevalence
varies from 1–20%, the probability of being an unidentified case
increases from 0.9–18.8%, respectively (Figure 2). To estimate the
number of unidentified cases, we performed an analysis based on a
hypothetical cohort of 1000 patients assuming that those disclosing
exposure would all be screened with a NAAT assay having 100%
sensitivity and specificity. The analysis was stratified by prevalence
of asymptomatic STI (0.01, 0.05, 0.10, 0.20). In our scenario, if all
patients who experienced unprotected anorectal exposure dis-
closed exposure, all would be screened and all cases identified.
Table 2. Prevalence of asymptomatic anorectal STI and operating characteristics of screening questions to predict asymptomatic
anorectal STI by sub-cohort.
Cohort & setting
Percentage
Disclosing
Exposure
Prevalence
Anal STI
Screening
Question
Sensitivity
Screening
Question
Specificity
Screening
Question
NPV
Screening
Question
PPV
TP
(n)
FN
(n)
FP
(n)
TN
(n)
Primary care Clinic using GC
culture/ CT DFA
70.7 (57.2 –81.9) 3.4 (0.4–11.9) 100 (15.8–100) 30.4 (18.8–44.1) 100 (80.5–100) 4.9 (0.60–16.5) 2 0 39 17
Primary care clinic using NAAT 70.6 (52.5–84.9) 21 (8.7–37.9) 85.7 (42.1–99.6) 33.3 (16.5–54) 90 (55.5–99.7) 25 (9.7–46.7) 6 1 18 9
HRA clinic using GC
culture/CT DFA
17.9 (14.9 –21.2) 4.2 (2.7–6.1) 12 (2.6–31.2) 81.8 (78.4–84.9) 95.5 (93.3–97.2) 2.8 (0.6–8) 3 22 104 468
HRA clinic using NAAT 14.8 (11.7–18.4) 4.3 (2.6–6.6) 35 (15.4–59.2) 86.1 (82.5–89.2) 96.7 (94.5–98.2) 10.1 (4.2–19.8) 7 13 62 384
Results expressed in percentage with parenthesis denoting 95 percentage confidence interval for each value.
Note: PPV=Positive predictive value. NPV=Negative predictive value. STI=sexually transmitted infection. HRA=High resolution anoscopy. GC=Neisseria gonorrhoeae.
CT=Chlamydia trachomatis. DFA=Direct fluorescent antibody assay.
NAAT=Nucleic acid amplification test.
TP=true positive. FN=false negative. FP=false positive. TN=true negative. n=number.
doi:10.1371/journal.pone.0008504.t002
Table 1. Sub-cohorts for screening of asymptomatic anorectal STI according to clinical setting and microbiology assay
methodologies.
Cohort Testing method Study period
Nu Men
n=803
Nu visits
n=1,155 Screening question
Primary care clinic Culture for GC, DFA CT 8/2/05–7/10/06 55 58 ‘‘During the past month, did your partner put his penis in your
anus without using a condom even once?’’
Primary care clinic NAAT GC/CT 11/1/08–3/31/09 34 34 ‘‘During the past month, did your partner put his penis in your
anus without using a condom even once?’’
HRA clinic Culture for GC, DFA CT 9/9/03–6/30/05 425 597 ‘‘During the last month, with how many people have you had
anal-receptive sex without using a condom?’’ (0 vs.$1)
HRA clinic NAAT GC/CT 8/4/08–11/10/09 408 466 ‘‘During the last month, with how many people have you had
anal-receptive sex without using a condom?’’ (0 vs.$1)
STI=Sexually transmitted infection. HRA=High Resolution Anoscopy. GC=Neisseria gonorrhoeae. CT=Chlamydia trachomatis. DFA=Direct fluorescent antibody assay.
NAAT=Nucleic acid amplification test.
doi:10.1371/journal.pone.0008504.t001
Rectal STI in HIV-Infected Men
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8504This would result in sensitivity for the screening question of 100%.
At the other extreme, if all who experienced unprotected anorectal
intercourse denied exposure, none would be screened and no cases
would be identified. The sensitivity of the screening question
would then be 0% (Figure 3). In our study, we found that the
proportion disclosing exposure was considerably lower in the HRA
clinic (14.8–17.9%) than in the primary care clinic (70.6–70.7%).
Discussion
The present study to assess the utility of self-disclosed
unprotected anorectal exposure to predict asymptomatic anorectal
STI found that:(1) the operating characteristics of the studied
screening questions were highly dependent upon screening setting
(primary care vs. HRA);(2) in all sub-cohorts, the prevalence of
self-reported unprotected anal-receptive intercourse varied con-
siderably by setting (primary care higher than HRA) but was
homogeneous within setting;(3) the number of self-disclosed sexual
partners in the preceding month may be a useful screening
selection criterion to identify patients at high risk for asymptomatic
anorectal STI;(4) despite agreement among primary care clinicians
to obtain anorectal microbiologic assays for patients identified
through behavioral screening to be at risk, the compliance rate was
poor with evidence that those with highest exposure risk were
selectively screened in comparison with those at lower exposure
risk; and (5) modeling the unidentified STI cases as the post
behavioral screening probability of STI (1–NPV) and as the
absolute number of unidentified cases highlights the importance of
background prevalence of anorectal STI and the proportion of
patients acknowledging anorectal risk behavior as key determi-
nants of the impact of a selective screening policy that limits
microbiologic testing to those acknowledging exposures.
Screening Setting Effect
The screening questions for unprotected anal- receptive
exposure performed more poorly in the HRA setting than in the
primary care setting. This could be attributed to different factors
other than setting itself. First, the questions were framed differently
in the two settings. In the primary care setting, the question was
part of a comprehensive sexual risk behavior instrument and asked
if there was even a single episode of unprotected anal-receptive
exposure during the prior month. In the HRA setting, the question
was imbedded in a brief questionnaire dealing with factors related
to the scheduled high resolution anoscopy and asked about the
number of partners with whom the patient had unprotected anal-
receptive exposure during the prior month. Second, in the primary
care setting, the patients completed the questionnaire as part of a
visit that was otherwise unrelated to an anogenital examination
Figure 1. Sensitivities and specificities of screening question to predict asymptomatic anorectal STI according to clinical setting
(‘primary care clinic vs. high resolution anoscopy clinic’) and microbiology assay method (‘GC culture and CT direct fluorescent
antibody vs. GC/CT nucleic acid amplification test’).
doi:10.1371/journal.pone.0008504.g001
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the questionnaire prior to an anticipated anorectal examination.
Differential Prevalence of Disclosed Risk Behaviors
We noted a striking difference in self-reported prevalence of
unprotected anal-receptive exposure between the two primary
care sub-cohorts (approximately 70%) and the two HRA sub-
cohorts (15–18%). While it is possible that these differences in
reported prevalence reflect differences in actual risk behavior
[10–12], we believe it likely that other factors are operative. In
favor of the differences being real, one could hypothesize that
those attending the HRA clinics, knowing that they had abnormal
anal cytology and were being referred to the HRA clinic, may
have reduced their risk behaviors during the month preceding the
examination. The prevalence of STI (3.5–4.3%) was similar in
both HRA sub-cohorts and the primary care sub-cohort requiring
for inclusion only one acknowledged sex partner during the prior
month. This would suggest that either actual behaviors over the
risk periods were similar in these 3 sub-cohorts or that
asymptomatic anorectal STI was prevalent for a longer period
of time in the HRA sub-cohorts. An alternative explanation for the
varying prevalence of reported risk behaviors in the two clinical
settings is differential functioning of social desirability bias due to
differences in question framing, screening context and perceived
normative expectations [13]. We believe it is unlikely that patients
would over-report sexual risk behaviors in either clinical context
(tending to decrease the specificity of the screening question) but
would rather tend to under-report risk behaviors in both settings
(tending to decrease sensitivity of the screening question).
Empirical research has identified methods to improve accuracy
of responses to intrusive or sensitive questions. A key finding of
that research is that self-administration of survey items is preferred
to interviewer-administration [14]. But it is not simply the physical
presence of another person during survey administration that
increases the probability of biased responding. ‘‘What seems to
matter is the threat that someone with whom the respondent will
continue to interact (an interviewer or bystander) will learn
something embarrassing about the respondent’’ [14]. During STI
screening, if self-reported risk behaviors are included in the
screening algorithm, it is essential to determine the actual risk-
behavior history. Relying only on clinicians, however, to assess risk
behaviors and then selectively screen with microbiology assays is
unlikely to result in a high-fidelity screening program.
Number of Partners as Risk Identifier
The high prevalence of asymptomatic anal STI in the primary
care sub-cohort employing NAAT could be due to the investigator
decision to limit eligibility to those men acknowledging at least
Figure 2. Sensitivity analysis of the probability of unidentified asymptomatic anorectal STI among those denying unprotected anal
receptive exposure. X-axis displays prevalence of asymptomatic STI (C. trachomatis and/or N. gonorrhoeae infection). Y-axis shows the probability
defined as one minus negative predictive value of the screening question.
doi:10.1371/journal.pone.0008504.g002
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this association post hoc analytically in the three other sub-cohorts
and found a statistically significant association between partner
number and STI prevalence in the HRA NAAT sub-cohort but
not in the other two sub-cohorts. While the association is
biologically plausible and consistent with other research [15–17],
there was no consistency among the sub-cohorts. A higher
observed prevalence in the primary care NAAT cohort could
have been due to a period effect of higher STI prevalence in the
community such that the same number of exposures would be
more likely to result in infection independent of the number of
partners involved.
Poor Clinician Compliance with Screening
Recommendations
A recent survey that examined data from HIV-infected MSM
receiving care at six cities in the United States from 2004 through
2006 found that only 5% of patients under care had been screened
for anorectal STI [3]. Our data from the primary care sub-cohorts
illustrates the challenge of integrating routine anorectal-STI
screening into HIV care settings. 24 and 79% of patients with
behavioral risk information lacked microbiologic data in the
primary care NAAT and primary care culture/DFA sub-cohorts,
respectively. We found that implementing routine behavioral
screening during the check-in process, supervised by a medical
assistant, greatly improved the documentation of risk behaviors in
comparison to a strategy that relied on clinician initiative to
document (data not shown). However, obtaining anal specimens
for microbiologic assay can only be performed by a qualified
clinician.
Modeling Undiagnosed Cases
The proportion of all STI cases not identified in a screening
question evaluation is estimated as the false negative proportion
(1–SE). The absolute number of unidentified cases depends on the
false negative proportion of the screening question and on the
prevalence of asymptomatic STI. In contrast, the post-behavioral
screen probability of STI (1–NPV) is dependent on both the
disease prevalence and the screening question operating charac-
teristics (SE, SP) [18]. Based on our data, we estimated that the
proportion of all cases that would be missed if microbiologic
screening were limited to patients acknowledging risk behavior
during the prior month varied from 11% in the primary care
setting to 78% in the HRA setting. The impact in terms of
absolute numbers of missed cases is directly related to disease
prevalence as illustrated in Figure 3, and, under a worst case
Figure 3. Model to estimate the number of unidentified cases based on a hypothetical cohort of 1000 patients, stratified by
prevalence of asymptomatic STI (0.01, 0.05, 0.10, 0.20). Model assumes that those disclosing unprotected anal receptive exposure would all
be screened with a NAAT assay having 100% sensitivity and specificity.
doi:10.1371/journal.pone.0008504.g003
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hypothetical cohort of 1,000 from 10 missed cases (STI prevalence
1%) to 200 cases (STI prevalence 20%). The range of
asymptomatic anal STI prevalence found in this study is similar
to those reported in other recent studies of MSM, including those
that are HIV infected [6,19–24]. What proportion or absolute
number of missed cases should trigger universal screening
regardless of acknowledged risk is best addressed by cost-
effectiveness analyses that include both risks for further transmis-
sion as well as morbidity in the index patients. Another question
not addressed by our data is the determination of an appropriate
screening interval and whether such an interval can be reliably
based on reported risk behaviors.
A number of additional limitations of our analysis should be
considered. First, we assumed that the microbiologic assays
performed as a perfect gold standard [25]. But published
sensitivities of the assays utilized were not perfect. Notwithstand-
ing, we have no reason to believe that the pattern of false negative
microbiologic assays would be differentially associated with
reported risk behaviors. Assuming that the screening questions
and microbiologic assays were conditionally independent, a bias
correction can be applied to adjust for the imperfect gold standard
assays [26]. The maximum absolute difference between unadjust-
ed and adjusted screening question sensitivity and specificity across
all four sub-cohorts was 0.08. With regard to specificity of the
NAAT assay, although quite high (.99%), our clinicians did not
routinely follow up positive NAAT results with culture prior to
treatment. Second, in both the primary care and HRA settings,
the screening question recall period was 1 month. To the extent
that asymptomatic anorectal STI could be present for longer than
1 month, the sensitivity of the screening question would be further
compromised by risk behaviors resulting in transmission prior to
the 1 month window. The longest documented duration of
asymptomatic anorectal gonococcal infection, to our knowledge,
was 165 days [27]. The CDC recommends a one-year risk
behavior recall period as part of the recommended screening
criteria [1]. However, in most HIV primary care settings patients
are routinely seen every 4 months as recommended by IDSA
guidelines [2]. Research in sexual risk behaviors has shown that
extending the question recall period beyond one month may
increase the likelihood of recall bias and make the data less reliable
especially in high risk populations such as the one that we studied
[28–29]. Third, we did not include syphilis or sexually transmitted
enteric pathogens in our definition of asymptomatic anorectal STI.
Conclusions
Under the conditions used in this study, denial of unprotected
anal-receptive exposure would lead, in our opinion, to an
unacceptable number and proportion of unidentified asymptom-
atic anorectal STI if used as a criterion not to obtain microbiologic
assays. The sensitivity and specificity of behavioral risk screening
questions can vary markedly by clinical setting and by question
framing. Improvement in screening question performance should
be based on findings of empirical research regarding survey
ascertainment of sensitive or stigmatized risk behaviors. Structur-
ing primary care encounters to facilitate routine collection of
anorectal microbiologic assays, even for patients with self-disclosed
risk behaviors, remains an ongoing challenge.
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